Literature DB >> 29932878

COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation.

Yan-Ping Wang1, Qu-Yuan Wang2, Chang-Hui Li3, Xue-Wei Li3.   

Abstract

Elevated cyclooxygenase-2 (COX-2) closely associates with tumor progression and distant metastasis in various human cancers. However, the role of COX-2 in epithelial ovarian cancer (EOC), and its mechanistic details, remain poorly understood. In the present study, we tested hypothesis that COX-2 induces loss of expression of E-cadherin, with resulting promotion of cancer cells' invasiveness in ovarian cancer. First, we observed an inverse relationship between COX-2 and E-cadherin expression as COX-2 was enhanced but E-cadherin was decreased in surgically-resected specimens of EOC. Depletion of COX-2, by celecoxib treatment, resulted in attenuated nuclear translocation of Snail, and, in turn, significantly increased E-cadherin in EOC cell line SKOV3, which was established to be due to the reduced binding of Snail onto E-cadherin promoter. Such COX-2 inhibition resulted in reduced invasion of EOC cells, similar to what was achieved through Snail silencing in SKOV as well as ES-2 EOC cells. These results suggest that COX-2-Snail signaling plays a critical role in regulation of E-cadherin and might provide insights into mechanisms for paracrine inflammation-mediated aggressiveness in EOC.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  COX-2; E-cadherin; EMT; Epithelial ovarian cancer; Snail

Mesh:

Substances:

Year:  2018        PMID: 29932878     DOI: 10.1016/j.cbi.2018.06.020

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  9 in total

1.  Diosgenin inhibits the epithelial-mesenchymal transition initiation in osteosarcoma cells via the p38MAPK signaling pathway.

Authors:  Huaming Huang; Chao Nie; Xiaokang Qin; Jie Zhou; Lei Zhang
Journal:  Oncol Lett       Date:  2019-08-23       Impact factor: 2.967

2.  Crowberry inhibits cell proliferation and migration through a molecular mechanism that includes inhibition of DEK and Akt signaling in cholangiocarcinoma.

Authors:  Xue Wang; Xuebing Zhou; Ludan Zhang; Xin Zhang; Chunyu Yang; Yingshi Piao; Jinhua Zhao; Lili Jin; Guihua Jin; Renbo An; Xiangshan Ren
Journal:  Chin Med       Date:  2022-06-13       Impact factor: 4.546

Review 3.  Targeting lipid metabolism in the treatment of ovarian cancer.

Authors:  Saliha Chaudhry; Stefani N Thomas; Glenn E Simmons
Journal:  Oncotarget       Date:  2022-05-25

4.  Nuclear translocation of β-catenin induced by E-cadherin endocytosis causes recurrent erosion of diabetic cornea.

Authors:  Wenbei Ma; Zhengyuan Xie; Hui Chen; Lina Zeng; Xiaohong Chen; Songfu Feng; Xiaohe Lu
Journal:  Exp Biol Med (Maywood)       Date:  2021-02-07

5.  Long Noncoding RNA VIM Antisense RNA 1 (VIM-AS1) Plays an Important Role in Development of Preeclampsia by Regulation of Epithelial Mesenchymal Transition.

Authors:  Xuehui Zhao; Xiaoying Jiang; Zongyin Liu; Mi Zhou; Juan Zhang; Xiaojing Wang; Xiaowen Li
Journal:  Med Sci Monit       Date:  2019-11-05

Review 6.  Cadherins, Selectins, and Integrins in CAM-DR in Leukemia.

Authors:  Hye Na Kim; Yongsheng Ruan; Heather Ogana; Yong-Mi Kim
Journal:  Front Oncol       Date:  2020-12-10       Impact factor: 6.244

7.  Inexpensive Systemic Inflammatory Biomarkers in Ovarian Cancer: An Umbrella Systematic Review of 17 Prognostic Meta-Analyses.

Authors:  Khalid El Bairi; Ouissam Al Jarroudi; Said Afqir
Journal:  Front Oncol       Date:  2021-09-23       Impact factor: 6.244

8.  Cyclooxygenase 2 Promotes Proliferation and Invasion in Ovarian Cancer Cells via the PGE2/NF-κB Pathway.

Authors:  Xiao Zhang; Keqin Yan; Lin Deng; Jing Liang; Haiyan Liang; Dingqing Feng; Bin Ling
Journal:  Cell Transplant       Date:  2019-12-10       Impact factor: 4.064

Review 9.  Deregulation of Lipid Metabolism: The Critical Factors in Ovarian Cancer.

Authors:  Zhaodong Ji; Yan Shen; Xu Feng; Yue Kong; Yang Shao; Jiao Meng; Xiaofei Zhang; Gong Yang
Journal:  Front Oncol       Date:  2020-10-19       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.